Drug Channels Archive for October, 2024

Click a link below to view the mailing archive as if it had been sent to you.

2024-10-29 07:39		Drug Channels News Roundup, October 2024: Humira Price War Update, PA vs. Providers, IRA vs. Physicians, My AI Podcast, New DCI Jobs, and Dr. G on Copayments
2024-10-25 07:47		Drug Channels - No More Delays: Accelerating Therapy Starts by Embedding Hub Services in Provider Workflows
2024-10-22 07:55		Drug Channels - The 340B Program Reached $66 Billion in 2023—Up 23% vs. 2022: Analyzing the Numbers and HRSA's Curious Actions
2024-10-21 07:47		Drug Channels - Informa Connect's Trade and Channel Strategies
2024-10-18 07:47		Drug Channels - The Promise of a Direct-to-Patient Model—Breaking Down What's Really Needed for Better Patient Access
2024-10-15 07:37		Drug Channels - If Plan Sponsors Are So Unhappy with Their PBMs' Transparency, Why Won't They Change the Model?
2024-10-11 07:47		Drug Channels - As MFP Approaches, Transparency Is More Important Than Ever
2024-10-09 07:40		Drug Channels - Five Crucial Trends Facing U.S. Drug Wholesalers in 2024 and Beyond
2024-10-08 07:47		Drug Channels - NOW AVAILABLE: 2024–25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors
2024-10-07 07:47		Drug Channels - Informa Connect's PBM Contracting Summit
2024-10-04 07:47		Drug Channels - Innovative Models for Improving Access and Visibility for Specialty-Lite and Retail Therapies
2024-10-03 07:47		Drug Channels - Another IRA Surprise: Part B Coinsurance Inflation Adjustments Are Increasing Patient Costs (rerun)
2024-10-01 07:34		Drug Channels - Why PBMs and Payers Are Embracing Insulin Biosimilars with Higher Prices—And What That Means for Humira (rerun with an FTC update)

<< Archive Index • Subscribe >>